Sugred
Generic Name
Dapagliflozin
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| sugred 80 mg tablet | ৳ 8.00 | ৳ 80.00 |
Description
Overview of the medicine
Sugred contains Dapagliflozin, an SGLT2 inhibitor, used to improve glycemic control in adults with type 2 diabetes mellitus, reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, and reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease.
Uses & Indications
Dosage
Adults
Recommended starting dose is 5 mg once daily, increasing to 10 mg once daily if needed and tolerated.
Elderly
No dose adjustment required based on age alone, but monitor renal function.
Renal_impairment
Initial dose 5 mg once daily. For eGFR <25 mL/min/1.73 m², initiation is not recommended, but current patients may continue with caution.
How to Take
Oral administration, once daily in the morning, with or without food.
Mechanism of Action
Dapagliflozin inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels. It also has beneficial effects on blood pressure and body weight.
Pharmacokinetics
Onset
Glycosuric effects observed within 30 minutes, peak by 2-4 hours.
Excretion
Mainly excreted in urine (75%) and feces (21%) as metabolites.
Half life
Approximately 12.9 hours in healthy subjects.
Absorption
Rapidly and well absorbed after oral administration. Peak plasma concentrations are typically reached within 2 hours.
Metabolism
Primarily metabolized by UGT1A9 to inactive metabolites.
Side Effects
Contraindications
- •Hypersensitivity to dapagliflozin or any component of Sugred
- •Severe renal impairment (eGFR <25 mL/min/1.73 m² if initiating treatment) or end-stage renal disease
- •Dialysis
Drug Interactions
Loop Diuretics
May increase the risk of dehydration and hypotension.
ACE Inhibitors/ARBs
May increase risk of hypotension and renal impairment.
Insulin or Insulin Secretagogues
Increased risk of hypoglycemia, dose adjustment may be needed.
Storage
Store below 30°C, in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
No specific antidote. Management includes supportive care, monitoring of hydration and electrolytes. Hemodialysis is unlikely to be effective.
Pregnancy & Lactation
Pregnancy Category C. Not recommended during the second and third trimesters of pregnancy due to potential adverse renal developmental effects. Not recommended during breastfeeding due to unknown excretion into human milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years
Availability
Pharmacies, hospitals
Approval Status
FDA approved (2014); DGDA approved
Patent Status
Patent protected (generic versions available in some regions)
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
